Biospecifics Tech Corp: (NASD: BSTC)
$15.62
-0.17 (-1.08%)
Volume 16,815
May 22 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 15.55 - 15.82 |
| 52wk Low - High | 12.52 - 21.99 |
| Previous Close | 15.79 |
| Avg. Volume | 20,650 |
| Industry | MED-DRUGS |
| Market Cap | 100.35 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.61 |
| PE (Forward) | 49.34 |
| Current Year Est. | 0.32 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
108 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 49.34 |
| PEG Ratio | 2.15 |
| Current Year Est. | 0.32 |
| Current Quarter Estimate | 0.00 |
| Most Accurate Estimate | 0.00 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | 0.52 |
| Expected Earnings Growth | 23.00% |
Company Description
BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.00 | -0.05 | 0.32 | 0.45 |
| Number of Estimates | 1 | 1 | 1 | 1 |
| Low Estimate | 0.00 | -0.05 | 0.32 | 0.45 |
| High Estimate | 0.00 | -0.05 | 0.32 | NA |
| Year Ago EPS | 0.10 | 0.07 | 0.43 | 0.32 |
| EPS Growth | -100.00% | -171.43% | -25.58% | 40.63% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| BIOSPECIFICS TE | BSTC | 15.79 | |
|
| JAZZ PHARMACEUT | JAZZ | 60.00 | |
|
| SALIX PHARM-LTD | SLXP | 59.33 | |
|
| SANTARUS INC | SNTS | 22.30 | |
|
| USANA HLTH SCI | USNA | 67.95 | |
|
| CATALYST PHARMA | CPRX | 0.91 | |
|
| CELL THERAPEUT | CTIC | 1.32 | |
|
| CUBIST PHARM | CBST | 55.46 | |
|
| ELAN CP PLC ADR | ELN | 12.07 | |
|
| INFINITY PHARMA | INFI | 25.13 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Company News for May 13, 2013
May 13, 2013
Positive Data on BSTC's Xiaflex
Apr 01, 2013
Standard Review for Auxilium's Drug
Dec 28, 2012
Weak Quarter from Auxilium Pharma
Nov 08, 2012
A Profitable Quarter for Auxilium
Aug 02, 2012
Report Not Available
Financials
| EPS TTM | 0.52 |
| Sales | 11 |
| Net Income | 4 |
| Price/Earnings | 30.36 |
| Price/Book | 5.39 |
| Price/Cash Flow | 33.19 |
| Price/Sales | 8.00 |
News
Earnings Scheduled For May 10, 2013 - Benzinga
May 10, 2013
Aegis Capital Reiterates Buy Rating on BioSpecifics Technologies Ahead of Conference Call - Benzinga
Mar 11, 2013
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) - GuruFocus
Nov 9, 2012
BioSpecifics Technologies Corp. Announces Presentation of Additional Phase III Data from XIAFLEX?? Clinical Trials for Peyronie`s Disease at SMSNA/ISSM Joint Annual Meeting - Benzinga
Aug 27, 2012
Health Care Sector Wrap - FOXBusiness.com
May 14, 2012
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) - GuruFocus
May 10, 2012
Health Care Sector Wrap - FOXBusiness.com
May 10, 2012
BioSpecifics Technologies Corp Announces Initiation of Phase II Trial for Canine Lipomas - Benzinga
May 7, 2012
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 29.00 |
| Industry Rank by ABR | 108 out of 265 |
| Rank in Industry | 16 out of 93 |
